The involvement of inflammasome-derived IL18 in AP was first indicated in a 2007 study in which the therapeutic effects of caspase-1 inhibitors in acute lung injury associated with AP were related with the inhibition of IL1β and IL18 [88]. The gene discussed is IL18; the disease is alkaline phosphatase measurement.